- Home
- INZY vs SCWO Comparison
INZY vs SCWO Comparison
Compare INZY & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- SCWO
- Stock Information
- Founded
- INZY 2015
- SCWO 2021
- Country
- INZY United States
- SCWO United States
- Employees
- INZY N/A
- SCWO N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- SCWO Environmental Services
- Sector
- INZY Health Care
- SCWO Utilities
- Exchange
- INZY Nasdaq
- SCWO Nasdaq
- Market Cap
- INZY 188.2M
- SCWO 186.8M
- IPO Year
- INZY 2020
- SCWO N/A
- Fundamental
- Price
- INZY $1.30
- SCWO $0.59
- Analyst Decision
- INZY Strong Buy
- SCWO
- Analyst Count
- INZY 8
- SCWO 0
- Target Price
- INZY $17.75
- SCWO N/A
- AVG Volume (30 Days)
- INZY 829.2K
- SCWO 412.9K
- Earning Date
- INZY 03-11-2025
- SCWO 11-13-2024
- Dividend Yield
- INZY N/A
- SCWO N/A
- EPS Growth
- INZY N/A
- SCWO N/A
- EPS
- INZY N/A
- SCWO N/A
- Revenue
- INZY N/A
- SCWO $313,930.00
- Revenue This Year
- INZY N/A
- SCWO N/A
- Revenue Next Year
- INZY N/A
- SCWO $5,180.00
- P/E Ratio
- INZY N/A
- SCWO N/A
- Revenue Growth
- INZY N/A
- SCWO N/A
- 52 Week Low
- INZY $1.29
- SCWO $0.54
- 52 Week High
- INZY $7.80
- SCWO $1.99
- Technical
- Relative Strength Index (RSI)
- INZY 19.59
- SCWO 24.81
- Support Level
- INZY $1.32
- SCWO $0.55
- Resistance Level
- INZY $1.44
- SCWO $0.68
- Average True Range (ATR)
- INZY 0.26
- SCWO 0.06
- MACD
- INZY -0.12
- SCWO 0.01
- Stochastic Oscillator
- INZY 0.53
- SCWO 21.59
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The business activities of the company include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.